Tradestie Institutional Equity Comparison Engine · Market Close Nov 02, 2026

MLEC vs LVRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLEC Captures Overall Composite Edge (40.8 SELL vs 41.1 SELL), While LVRO Leads 5–0 on Growth & Valuation Pillars

MLEC Overall Winner 6-Pillar Tally: MLEC 0 – 5 LVRO (1 Tie) Matrix Metrics: MLEC 3 – 6 LVRO

As of Nov 02, 2026, Moolec Science SA (MLEC) captures the overall head-to-head institutional edge over Lavoro Limited Class A (LVRO) on higher Unified Composite conviction (40.8/100 SELL vs. 41.1/100 SELL) after splitting the core matrix 3–6 (led by composite factor balance), while LVRO wins 5–0 across the 6-pillar growth and valuation breakdown. MLEC trades at $0.85 (N/M Forward P/E, 0.0% operating margin) versus LVRO at $0.30 (63.7x Forward P/E, 0.2% operating margin).

  • Growth vs. Quality Trade-Off: MLEC earns the overall head-to-head edge with a stronger Unified Composite Score (40.8/100 SELL vs. LVRO 41.1/100 SELL) and 0.05β · 208% Vol risk profile, whereas LVRO leads top-line expansion (-13.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although MLEC compares more favorably head-to-head, both MLEC (40.8/100 SELL) and LVRO (41.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MLEC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.8); meanwhile LVRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLEC vs LVRO
MLEC NASDAQ Head-to-Head Winner
Moolec Science SA Ordinary Shares
Textile Mill Products
$0.85
-39.29% 1D
Market Cap $1.0M
TTM Revenue $7.8M
Forward P/E N/M
Beta / 30D Vol 0.05β · 208% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.9%), weak momentum, RSI 17
RSI-14: 16.8 · SMA20: $2.06 · SMA50: $4.58
LVRO NASDAQ
Lavoro Limited Class A Ordinary Shares
Retail-Miscellaneous Retail
$0.30
-24.42% 1D
Market Cap $60.8M
TTM Revenue $9.08B
Forward P/E 63.7x
Beta / 30D Vol 1.04β · 160% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 55.0 Fund 46.0 Flow 50.0 Mom 26.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 21
RSI-14: 21.4 · SMA20: $0.94 · SMA50: $0.89

6-Pillar Scorecard Institutional Category Breakdown (MLEC 0 – 5 LVRO)

Columns: Metric · MLEC · LVRO
1. Valuation Multiples LVRO
Forward P/E N/M 63.7x
Trailing P/E N/M 63.7x
PEG Ratio N/M N/M
EV / Revenue 0.1x N/M
2. Growth & Scale LVRO
Revenue Growth (YoY) +948.3% -13.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.8M $9.08B
Market Cap $1.0M $60.8M
3. Profitability & Quality LVRO
Gross Margin -8.2% 15.0%
Operating Margin 0.0% 0.2%
Net Profit Margin 0.0% -10.4%
Return on Equity (ROE) -174.7% -62.4%
4. Balance Sheet & Cash Flow LVRO
Cash Generation (TTM) -$8.1M EBITDA $106M EBITDA
Cash Flow Margin -103.1% EBITDA Mgn 1.2% EBITDA Mgn
Net Cash / Leverage $0.70 Book/Sh · -174.7% ROE $1.35 Book/Sh · -62.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat LVRO
OpEx & R&D Intensity N/A 14.8% of Rev ($1.34B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Agricultural Inputs Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLEC (3) vs LVRO (6)
Institutional Metric MLEC LVRO Criterion Row Edge
Market Capitalization
Scale
$1.0M $60.8M Larger Scale LVRO
Trailing P/E Ratio
Valuation
N/M 63.7x Lower Multiple LVRO
Forward P/E Ratio
Valuation
N/M 63.7x Lower Multiple LVRO
Revenue Growth (YoY)
Growth
+948.3% -13.2% Higher Growth MLEC
Operating Margin (TTM)
Profitability
0.0% 0.2% Higher Margin Tie
Net Profit Margin
Profitability
0.0% -10.4% Higher Margin MLEC
Return on Equity (ROE)
Capital Efficiency
-174.7% -62.4% Higher ROE LVRO
52-Week Range Position
Momentum
3% ($0–$23) 2% ($0–$5) Stronger Trend MLEC
Beta / 30D Volatility
Risk Regime
0.05β · 208% Vol 1.04β · 160% Vol Lower Realized Risk LVRO
Unified Institutional Score
Composite Signal
40.8 / 100 (SELL) 41.1 / 100 (SELL) Higher Composite LVRO
Trailing 12M Revenue (USD)
Operating Scale
$7.8M $9.08B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-8.2% 15.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.1M EBITDA ($0.70 Book/Sh · -174.7% ROE) $106M EBITDA ($1.35 Book/Sh · -62.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLEC +208.5 pp
MLEC: +136.14% · LVRO: -72.36%
3M Horizon MLEC +2818.5 pp
MLEC: +2744.71% · LVRO: -73.79%
6M Horizon MLEC +2546.56 pp
MLEC: +2468.59% · LVRO: -77.97%
1Y Horizon MLEC +2546.56 pp
MLEC: +2468.59% · LVRO: -77.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLEC vs LVRO. Trailing 12-month operating profitability (MLEC 0.0% vs LVRO 0.2%) and valuation multiples (MLEC N/M vs LVRO 63.7x Forward P/E) are benchmarked directly in Pillar 4 below.

MLEC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.8M
Gross Margin-8.2%
Op. Margin0.0%
ROE / Fwd P/E-174.7% · N/M
LVRO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$9.08B
Gross Margin15.0%
Op. Margin0.2%
ROE / Fwd P/E-62.4% · 63.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLEC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MLEC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LVRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LVRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLEC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LVRO Moat Profile Cyclical / Execution-Driven Positioning
Agricultural Inputs Operator
Competes within the Agricultural Inputs value chain with $60.8M market capitalization and 0.2% operating margin.
OpEx & R&D Reinvestment 14.8% of Rev ($1.34B)
90D Engineering Disclosures 0 Published

Investor FAQ MLEC vs LVRO Key Questions & Quantitative Answers

As of Nov 02, 2026, Moolec Science SA (MLEC) captures the overall head-to-head institutional edge over Lavoro Limited Class A (LVRO) on higher Unified Composite conviction (40.8/100 SELL vs. 41.1/100 SELL) after splitting the core matrix 3–6 (led by composite factor balance), while LVRO wins 5–0 across the 6-pillar growth and valuation breakdown. MLEC trades at $0.85 (N/M Forward P/E, 0.0% operating margin) versus LVRO at $0.30 (63.7x Forward P/E, 0.2% operating margin). Growth vs. Quality Trade-Off: MLEC earns the overall head-to-head edge with a stronger Unified Composite Score (40.8/100 SELL vs. LVRO 41.1/100 SELL) and 0.05β · 208% Vol risk profile, whereas LVRO leads top-line expansion (-13.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although MLEC compares more favorably head-to-head, both MLEC (40.8/100 SELL) and LVRO (41.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MLEC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.8); meanwhile LVRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LVRO leads the Growth & Scale pillar: MLEC posts +948.3% YoY revenue growth and +0.0% YoY earnings growth on $7.8M TTM revenue (-8.2% gross margin, 0.0% operating margin), compared with LVRO at -13.2% YoY revenue growth and +0.0% YoY earnings growth on $9.08B TTM revenue (15.0% gross margin, 0.2% operating margin). On trailing 12-month operating scale, MLEC generates $7.8M in USD-normalized revenue versus $9.08B for LVRO. In operating R&D and SG&A reinvestment, MLEC deploys N/A (0 90-day corporate R&D disclosures) versus 14.8% of Rev ($1.34B) (0 disclosures) for LVRO.

LVRO screens cheaper on headline valuation multiples. MLEC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-103.1% EBITDA margin), whereas LVRO trades at 63.7x Forward P/E, 63.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (1.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLEC (-174.7% ROE) versus LVRO (-62.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MLEC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.05β · 208% Vol realized risk). By comparison, LVRO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 160% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 02, 2026. For educational research only; not investment advice.